



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Gene Therapy for Inherited Retinal Dystrophy

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Endnotes](#)

Policy Number: 911

BCBSA Reference Number: 2.04.144 (For Plan internal use only)

NCD/LCD: NA

Related Policies

None

Policy

**Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members**

Preauthorization Request Form: Gene Therapy for Inherited Retinal Dystrophy

This form **must** be completed and faxed to: **Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994.**

Click here for [Gene Therapy for Inherited Retinal Dystrophy Preauthorization Request Form, #926](#)

Voretigene neparvovec-rzyl adeno-associated virus vector-based gene therapy subretinal injection is considered **MEDICALLY NECESSARY** for patients with vision loss due to biallelic *RPE65* pathogenic or likely pathogenic¹ variant-associated retinal dystrophy if they meet all of the following criteria:

- Are adults (age <65 years) or children (age ≥3 years)
- Documentation of the following:
 - Genetic testing confirming presence of bilallelic RPE65 pathogenic or likely pathogenic¹ variant(s)*
 - Single RPE65 pathogenic or likely pathogenic¹ variant found in the homozygous state
 - Two RPE65 pathogenic or likely pathogenic¹ variants found in the trans configuration (compound heterozygous state) by segregation analysis
 - Presence of viable retinal cells as determined by treating physicians as assessed by optical coherence tomography imaging and/or ophthalmoscopy:
 - An area of retina within the posterior pole of >100 μm thickness shown on optical coherence tomography, OR
 - ≥3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole, OR

- Any remaining visual field within 30° of fixation as measured by III4e/V4e isopter equivalent, OR
 - Measureable full-field light sensitivity threshold (FST).
- Do not have any of the following:
 - Pregnancy in females.
 - Breastfeeding.
 - Use of prescription retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme; individuals who discontinue use of these compounds for 3 months may become eligible.
 - Prior intraocular surgery within 3 months.
 - Preexisting eye conditions or complicating systemic diseases that would eventually lead to irreversible vision loss and prevent the patient from receiving full benefit from Voretigene neparvovec-rzyl (eg, leukemia with central nervous system/optic nerve involvement, severe diabetic retinopathy).
 - Patients with immunodeficiency (acquired or congenital) because they could be susceptible to opportunistic infection (eg, cytomegalovirus retinitis).

***Diagnosis of Biallelic RPE65-Mediated Inherited Retinal Dystrophies**

Genetic testing is required to detect the presence of pathogenic(s) variants in the *RPE65* gene. By definition, pathogenic variant(s) must be present in both copies of the *RPE65* gene to establish a diagnosis of biallelic *RPE65*-mediated inherited retinal dystrophy.

A single *RPE65* pathogenic variant found in the homozygous state (eg, the presence of the same pathogenic variant in both copies alleles of the *RPE65* gene) establishes a diagnosis of biallelic *RPE65*-mediated dystrophinopathy.

However, if 2 different *RPE65* pathogenic variants are detected (eg, compound heterozygous state), confirmatory testing such as segregation analysis by family studies may be required to determine the *trans* vs *cis* configuration (eg, whether the 2 different pathogenic variants are found in different copies or in the same copy of the *RPE65* gene). The presence of 2 different *RPE65* pathogenic variants in separate copies of the *RPE65* gene (*trans* configuration) establishes a diagnosis of biallelic *RPE65*-mediated dystrophinopathy. The presence of 2 different *RPE65* pathogenic variants in only 1 copy of the *RPE65* gene (*cis* configuration) is not considered a biallelic *RPE65*-mediated dystrophinopathy.

Next-generation sequencing and Sanger sequencing typically cannot resolve the phase (eg, *trans* vs *cis* configuration) when two *RPE65* pathogenic variants are detected. In this scenario, additional documentation of the *trans* configuration is required to establish a diagnosis of biallelic *RPE65*-mediated inherited retinal dystrophy. Table PG1 provides a visual representation of the genetic status requirements to establish a diagnosis of *RPE65*-mediated inherited retinal dystrophy.

Table PG1. Genetic Diagnosis of RPE65-Mediated Inherited Retinal Dystrophy

Genetic Status	Diagram	Diagnosis of RPE65-Mediated Inherited Retinal Dystrophy?
Homozygous	RPE65 gene copy #1 (- - - - - X - - - - -) RPE65 gene copy #2 (- - - - - X - - - - -) X=single RPE65 pathogenic variant	Yes
Heterozygous (<i>trans</i> configuration)	RPE65 gene copy #1 (- - - - - X - - - - -) RPE65 gene copy #2 (- - - O - - - - -) X=RPE65 pathogenic variant #1 O=RPE65 pathogenic variant #2	Yes
Heterozygous (<i>cis</i> configuration)	RPE65 gene copy #1 (- - O - - X - - - - -) RPE65 gene copy #2 (- - - - - - - - - - -)	No

	X=RPE65 pathogenic variant #1 O=RPE65 pathogenic variant #2	
--	--	--

Other applications of voretigene neparvovec-rzyl are considered [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	*Prior authorization is required .
Commercial PPO and Indemnity	*Prior authorization is required .
Medicare HMO Blue SM	*Prior authorization is required .
Medicare PPO Blue SM	*Prior authorization is required .

*Preauthorization Request Form: Gene Therapy for Inherited Retinal Dystrophy

This form **must** be completed and faxed to: Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994.

Click here for [Gene Therapy for Inherited Retinal Dystrophy Preauthorization Request Form, #926](#)

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

HCPCS Codes

HCPCS codes:	Code Description
C9399	Unclassified drugs or biological
C9770	Vitrectomy, mechanical, pars plana approach, with subretinal injection of pharmacologic/biologic agent
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
J3490	Unclassified drugs
J3590	Unclassified biologics

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
-----------------------------	------------------

3E0C3GC	Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach
3E0CXGC	Introduction of Other Therapeutic Substance into Eye, External Approach

Description

Inherited Retinal Dystrophies

Inherited retinal dystrophies are a diverse group of disorders with overlapping phenotypes characterized by progressive degeneration and dysfunction of the retina.¹ The most common subgroup is retinitis pigmentosa, which is characterized by a loss of retinal photoreceptors, both cones, and rods. The hallmark of the condition is night blindness (nyctalopia) and loss of peripheral vision. These losses lead to difficulties in performing visually dependent activities of daily living such as orientation and navigation in dimly lit areas. Visual acuity may be maintained longer than peripheral vision, though eventually, most individuals progress to vision loss.

RPE65 Gene

Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) both have subtypes related to pathogenic variants in *RPE65*. *RPE65* (retinal pigment epithelium-specific protein 65-kD) gene encodes the RPE54 protein is an all-trans-retinal isomerase, a key enzyme expressed in the retinal pigment epithelium (RPE) that is responsible for regeneration of 11-*cis*-retinol in the visual cycle.² The *RPE65* gene is located on the short (p) arm of chromosome 1 at position 31.3 (1p31.3). Individuals with biallelic variations in *RPE65* lack the RPE65 enzyme; this lack leads to build-up of toxic precursors and damage to RPE cells, loss of photoreceptors, and eventually complete blindness.³

Epidemiology

RPE65-associated inherited retinal dystrophy is rare. The prevalence of LCA has been estimated to be between 1 in 33000 and 1 in 81000 individuals in the United States.^{4,5} LCA subtype 2 (*RPE65*-associated LCA) accounts for between 5% and 16% of cases of LCA.^{4,6,7,8} The prevalence of RP in the United States is approximately 1 in 3500 to 1 in 4000⁹, with approximately 1% of patients with RP having *RPE65* variants.¹⁰ Assuming a United States population of approximately 330.6 million at the end of 2020,¹¹ the prevalence of *RPE65*-associated retinal dystrophies in the United States would, therefore, be roughly 1000 to 2500 individuals. Table 1 summarizes the estimated pooled prevalence of *RPE65*-associated inherited retinal dystrophy and the range of estimated cases based on the estimated 2017 United States population.

Table 1. Estimated Pooled Prevalence of RPE65-Associated Inherited Retinal Dystrophy and Estimated Number of Patients

Description	Low	High
Estimated pooled prevalence of <i>RPE65</i> -mediated inherited retinal dystrophies (eg, LCA type 2, <i>RPE65</i> -mediated RP)	1:330,000	1:130,000
Estimated number of patients	1,000	2,500

LCA type 2: Leber congenital amaurosis type 2; RP: retinitis pigmentosa.

Gene Therapy

Gene therapies are treatments that change the expression of genes to treat disease, eg, by replacing or inactivating a gene that is not functioning properly or by introducing a new gene. Genes may be introduced into human cells through a vector, usually a virus.¹² Adeno-associated viruses (AAV) are frequently used due to their unique biology and simple structure. These viruses are in the parvovirus family and are dependent on coinfection with other viruses, usually adenoviruses, to replicate. AAVs are poorly immunogenic compared with other viruses but can still trigger immune response making it a challenge to deliver an effective dose without triggering an immune response that might render the gene therapy ineffective or harm the patient.³ There are over 100 different AAVs, and 12 serotypes have been identified so far, labeled AAV1 to AAV12; in particular, AAV2, AAV4, and AAV5 are specific for retinal tissues. The recombinant AAV2 is the most commonly used AAV serotype in gene therapy.¹³

The eye is a particularly appropriate target for gene therapy due to the immune privilege provided by the blood-ocular barrier and the minimal amount of vector needed, given the size of the organ. Gene therapy for *RPE65* variant-associated retinal dystrophy using various AAV vectors to transfect cells with a functioning copy of *RPE65* in the RPE cells has been investigated.

Summary

Inherited retinal dystrophy can be caused by recessive variants in the *RPE65* gene. Patients with biallelic variants have difficulty seeing in dim light and progressive loss of vision. These disorders are rare and have traditionally been considered untreatable. Gene therapy with an adeno-associated virus vector expressing RPE65 has been proposed as a treatment to improve visual function.

For individuals who have vision loss due to biallelic *RPE65* variant-associated retinal dystrophy who receive gene therapy, the evidence includes RCTs and uncontrolled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Biallelic *RPE65* variant-associated retinal dystrophy is a rare condition and, as such, it is recognized that there will be particular challenges in generating evidence, including recruitment for adequately powered RCTs, validation of novel outcome measures, and obtaining longer-term data on safety and durability. There are no other U.S. Food and Drug Administration approved pharmacologic treatments for this condition. One RCT (N=31) comparing voretigene neparvovec with a control demonstrated greater improvements on the Multi-Luminance Mobility Test, which measures the ability to navigate in dim lighting conditions. Most other measures of visual function were also significantly improved in the voretigene neparvovec group compared with the control group. Adverse events were mostly mild to moderate. However, there is limited follow-up available. Therefore, the long-term efficacy and safety are unknown. Based on a small number of patients from early phase studies, voretigene neparvovec appears to have durable effects to at least 4 years. Other gene therapies tested in early phase trials have shown improvements in retinal function but variable durability of effect; some patients from 2 cohorts who initially experienced improvements have subsequently experienced declines after 1 to 3 years. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
3/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Clarified coding information
3/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Clarified coding information.
9/2018	Policy criteria clarified. 9/13/2018
7/2018	Clarified coding information.
2/1/2018	New medical policy describing medically necessary and investigational indications. Effective 2/1/2018.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet*. Nov 18 2006; 368(9549): 1795-809. PMID 17113430
2. Jin M, Li S, Moghrabi WN, et al. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. *Cell*. Aug 12 2005; 122(3): 449-59. PMID 16096063
3. Naso MF, Tomkowicz B, Perry WL, et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. *BioDrugs*. Aug 2017; 31(4): 317-334. PMID 28669112
4. Stone EM. Leber congenital amaurosis - a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. *Am J Ophthalmol*. Dec 2007; 144(6): 791-811. PMID 17964524
5. Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human retinal development. *Surv Ophthalmol*. Jul-Aug 2004; 49(4): 379-98. PMID 15231395
6. den Hollander AI, Roepman R, Koenekoop RK, et al. Leber congenital amaurosis: genes, proteins and disease mechanisms. *Prog Retin Eye Res*. Jul 2008; 27(4): 391-419. PMID 18632300
7. Astuti GD, Bertelsen M, Preising MN, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. *Eur J Hum Genet*. Jul 2016; 24(7): 1071-9. PMID 26626312
8. Kumaran N, Moore AT, Weleber RG, et al. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. *Br J Ophthalmol*. Sep 2017; 101(9): 1147-1154. PMID 28689169
9. Haim M. Epidemiology of retinitis pigmentosa in Denmark. *Acta Ophthalmol Scand Suppl*. 2002; (233): 1-34. PMID 11921605
10. Morimura H, Fishman GA, Grover SA, et al. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. *Proc Natl Acad Sci U S A*. Mar 17 1998; 95(6): 3088-93. PMID 9501220
11. United States Census Bureau. U.S. and World Population Clock. 2020; <https://www.census.gov/popclock/>. Accessed November 19, 2020.
12. FDA Advisory Committee Briefing Document: Spark Therapeutics, Inc, LuxturnaTM (voretigene neparvovec). 2017; <https://www.fda.gov/media/108385/download>. Accessed November 19, 2020.
13. Campa C, Gallenga CE, Bolletta E, et al. The Role of Gene Therapy in the Treatment of Retinal Diseases: A Review. *Curr Gene Ther*. 2017; 17(3): 194-213. PMID 29149824
14. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet*. Aug 26 2017; 390(10097): 849-860. PMID 28712537
15. Beck RW, Maguire MG, Bressler NM, et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. *Ophthalmology*. Oct 2007; 114(10): 1804-9. PMID 17908590
16. Bittner AK, Gould JM, Rosenfarb A, et al. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients. *Clin Exp Optom*. May 2014; 97(3): 240-7. PMID 24773463
17. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. *Ophthalmology*. Nov 2001; 108(11): 1943-53. PMID 11713061
18. Gillespie BW, Musch DC, Niziol LM, et al. Estimating minimally important differences for two vision-specific quality of life measures. *Invest Ophthalmol Vis Sci*. Jun 06 2014; 55(7): 4206-12. PMID 24906863
19. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. *Ophthalmic Epidemiol*. Jul-Aug 2007; 14(4): 205-15. PMID 17896299
20. Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. *Clin Exp Ophthalmol*. Apr 2018; 46(3): 247-259. PMID 28697537
21. Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. *Ophthalmology*. Sep 2019; 126(9): 1273-1285. PMID 31443789
22. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med*. May 22 2008; 358(21): 2240-8. PMID 18441370

23. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. *Lancet*. Nov 07 2009; 374(9701): 1597-605. PMID 19854499
24. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. *Mol Ther*. Mar 2010; 18(3): 643-50. PMID 19953081
25. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. *J Clin Invest*. Jun 2011; 121(6): 2160-8. PMID 21606598
26. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. *Sci Transl Med*. Feb 08 2012; 4(120): 120ra15. PMID 22323828
27. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. *Ophthalmology*. Jun 2013; 120(6): 1283-91. PMID 23474247
28. Ashtari M, Zhang H, Cook PA, et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis. *Sci Transl Med*. Jul 15 2015; 7(296): 296ra110. PMID 26180100
29. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. *Lancet*. Aug 13 2016; 388(10045): 661-72. PMID 27375040
30. Ashtari M, Nikonova ES, Marshall KA, et al. The Role of the Human Visual Cortex in Assessment of the Long-Term Durability of Retinal Gene Therapy in Follow-on RPE65 Clinical Trial Patients. *Ophthalmology*. Jun 2017; 124(6): 873-883. PMID 28237426
31. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. *N Engl J Med*. May 22 2008; 358(21): 2231-9. PMID 18441371
32. Stieger K. tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. *Curr Opin Mol Ther*. Aug 2010; 12(4): 471-7. PMID 20677098
33. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. *N Engl J Med*. May 14 2015; 372(20): 1887-97. PMID 25938638
34. Ripamonti C, Henning GB, Robbie SJ, et al. Spectral sensitivity measurements reveal partial success in restoring missing rod function with gene therapy. *J Vis*. 2015; 15(15): 20. PMID 26605849
35. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. *Hum Gene Ther*. Oct 2008; 19(10): 979-90. PMID 18774912
36. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proc Natl Acad Sci U S A*. Sep 30 2008; 105(39): 15112-7. PMID 18809924
37. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. *Hum Gene Ther*. Sep 2009; 20(9): 999-1004. PMID 19583479
38. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. *N Engl J Med*. Aug 13 2009; 361(7): 725-7. PMID 19675341
39. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. *Arch Ophthalmol*. Jan 2012; 130(1): 9-24. PMID 21911650
40. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. *Proc Natl Acad Sci U S A*. Feb 05 2013; 110(6): E517-25. PMID 23341635
41. Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudo-fovea formation after gene therapy for RPE65-LCA. *Invest Ophthalmol Vis Sci*. Dec 23 2014; 56(1): 526-37. PMID 25537204
42. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. *N Engl J Med*. May 14 2015; 372(20): 1920-6. PMID 25936984
43. Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. *Hum Gene Ther*. Dec 2010; 21(12): 1749-57. PMID 20604683

44. Weleber RG, Pennesi ME, Wilson DJ, et al. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. *Ophthalmology*. Jul 2016; 123(7): 1606-20. PMID 27102010
45. Pennesi ME, Weleber RG, Yang P, et al. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. *Hum Gene Ther*. Dec 2018; 29(12): 1428-1437. PMID 29869534
46. Le Meur G, Lebranchu P, Billaud F, et al. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. *Mol Ther*. Jan 03 2018; 26(1): 256-268. PMID 29033008
47. Spark Therapeutics. FDA Advisory Committee Briefing Document: Spark Therapeutics, Inc, Luxturna™ (voretigene neparvovec). 2017; <https://www.fda.gov/media/108385/download>. Accessed December 9, 2019.
48. National Institute for Health and Care Excellence (NICE). Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations [HST11]. October 9, 2019. <http://nice.org.uk/guidance/hst11>. Accessed November 19, 2020.

Endnotes

¹ Based on expert opinion